Current Treatment Options in Psychiatry

, Volume 6, Issue 1, pp 1–16 | Cite as

Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis

  • Jean AddingtonEmail author
  • Daniel J. Devoe
  • Olga Santesteban-Echarri
Schizophrenia and Other Psychotic Disorders (J Csernansky, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Schizophrenia and Other Psychotic Disorders



One of the goals of identifying youth identified, based on clinical symptoms, as being at risk for developing psychosis, is to find ways to prevent or even delay the onset of the illness. Over the past 20 years, relatively few randomized control trials (RCTs), including both pharmacological and psychosocial interventions, have been conducted and often with inconsistent results. Several recent meta-analyses suggest that there are few treatments if any that might be effective and that no one treatment is seen as being more effective than any other treatment. This review aims to examine the existing RCTs and to critically review recent meta-analyses.

Recent findings

Individuals at clinical high risk for psychosis are a heterogeneous group. Unfortunately, many interventions have not been specifically designed to address the outcome being assessed nor have participants been specifically selected for that treatment.


The trials completed to date and the recent systematic reviews should be seen positively and used to guide the design of future trials to ensure that the right interventions are offered to the right people at the right time.


Psychosis Prodrome Clinical trials Clinical high risk Meta-analyses Treatment 


Funding information

Preparation of this article was supported by the National Institute of Mental Health Grant MH105178 to Jean Addington. Olga Santesteban-Echarri is supported by a Canadian Institutes of Health Research post-doctoral scholarship and Dan Devoe by an Alberta Innovates Graduate Scholarship.

Compliance with ethical standards

Conflict of interest

Jean Addington declares no conflict of interest. Daniel Devoe declares no conflict of interest. Olga Santesteban-Echarri declares no conflict of interest.

Human and animal rights and informed consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    McGlashan T, Walsh B, Woods S. The psychosis-risk syndrome: handbook for diagnosis and follow-up. Oxford University Press; 2010.Google Scholar
  2. 2.
    Yung AR, Yuen HP, PD MG, Phillips LJ, Kelly D, Dell’Olio M, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry. 2005;39(11–12):964–71. Scholar
  3. 3.
    Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia proneness instrument, adult version (SPI-A). Rome: Giovanni Fiorito Editore; 2007.Google Scholar
  4. 4.
    Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res. 2011;125(1):54–61. Scholar
  5. 5.
    Morrison AP, Fench P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Randomised controlled trial. Br J Psychiatry. 2004;185:291–7.CrossRefGoogle Scholar
  6. 6.
    Morrison AP, French P, Stewart SLK, Birchwood M, Fowler D, Gumley AI, et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ. 2012;344:1–14.Google Scholar
  7. 7.
    Stain HJ, Bucci S, Baker AL, Carr V, Emsley R, Halpin S, et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reflective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophr Res J. 2016;176(2–3):212–9.CrossRefGoogle Scholar
  8. 8.
    Van Der Gaag M, Nieman DH, Rietdijk J, Dragt S, Ising HK, Klaassen RMC, et al. Cognitive behavioral therapy for subjects at ultra high risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull. 2012;38(6):1180–8. Scholar
  9. 9.
    Miklowitz DJ, O'Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. 2014;53(8):848–58. Scholar
  10. 10.
    Choi J, Corcoran CM, Fiszdon JM, Stevens M, Javitt DC, Deasy M, et al. Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis. Psychiatr Rehabil J. 2017;40(1):33–42. Scholar
  11. 11.
    Loewy R, Fisher M, Schlosser DA, Biagianti B, Stuart B, Mathalon DH, et al. Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis. Schizophr Bull. 2016;42(Suppl 1):S118–26. Scholar
  12. 12.
    • Piskulic D, Barbato M, Liu L, Addington J. Pilot study of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis. Psychiatry Res. 2015;225(1–2):93–8. Up to date systematic review and network meta-analysis of treatments to prevent transition to psychosis.Google Scholar
  13. 13.
    Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry. 2012;200(1):22–9. Scholar
  14. 14.
    McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921–8.CrossRefGoogle Scholar
  15. 15.
    •• McGorry P, Nelson B, Phillips LJ, Yuen HP, Francey 537 SM, Thampi A, et al. Randomized controllled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. 2013;74(4):349–56. Up to date systematic review and network meta-analysis of treatments and attenuated psychotic symptoms.Google Scholar
  16. 16.
    Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–54. Scholar
  17. 17.
    Cadenhead K, Addington J, Cannon T, Cornblatt B, Mathalon D, McGlashan T, et al. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal Studies (NAPLS) Consortium. Schizophr Bull. 2017;43(suppl_1):S16. Scholar
  18. 18.
    McGorry P, Nelson B, Markulev C, Yuen H, Schafer M, Mossaheb N, et al. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiat. 2017;74(1):19–27.CrossRefGoogle Scholar
  19. 19.
    Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM. Chen H et al. “D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial”: correction. Lancet Psychiatry. 2016;3(7):602.CrossRefGoogle Scholar
  20. 20.
    Woods S, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, et al. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol. 2013;23(8):931–40. Scholar
  21. 21.
    Ruhrmann S, Bechdolf A, Kuhn KU, Wagner M, Schultze-Lutter F, Janssen B, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry. 2007;191(SUPPL. 51):s88–95.CrossRefGoogle Scholar
  22. 22.
    McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790–9. Scholar
  23. 23.
    Woods S, Saksa J, Compton M, Daley M, Rajarethinam R, Graham K et al. Effects of ziprasidone versus placebo in patients at clinical high risk for psychosis. Schizophr Bull. 2017;Conference(States):16th International Congress on Schizophrenia Research.Google Scholar
  24. 24.
    French P, Morrison AP. Early detection and cognitive therapy for people at high risk of developing psychosis. West Sussex: John Wiley & Sons; 2004.CrossRefGoogle Scholar
  25. 25.
    Ising HK, Kraan TC, Rietdijk J, Dragt S, Klaassen RMC, Boonstra N, et al. Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch early detection intervention evaluation (EDIE-NL) trial. Schizophr Bull. 2016;42(5):124–52.CrossRefGoogle Scholar
  26. 26.
    Devoe DJ, Farris MS, Townes P, Addington J. Interventions and transition in youth at risk of psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2018;12(1):173.Google Scholar
  27. 27.
    Davies C, Cipriani A, Ioannidis JPA, Radua J, Stahl D, Provenzani U, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry. 2018;17(2):196–209. Scholar
  28. 28.
    Devoe DJ, Peterson A, Addington J. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. Schizophr Bull. 2017.
  29. 29.
    Devoe DJ, Farris MS, Townes P, Addington J. Interventions and social functioning in youth at risk of psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2018.
  30. 30.
    Devoe DJ, Farris MS, Townes P, Addington J. Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2018.
  31. 31.
    Davies C, Radua J, Cipriani A, Stahl D, Provenzani U, McGuire P, et al. Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. Front Psych. 2018;9:187. Scholar
  32. 32.
    Devoe DJ, Farris MS, Addington J. Symptoms of depression and anxiety in youth at risk for psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2018;12(1):174.Google Scholar
  33. 33.
    International, Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry. 2005;187(SUPPL. 48):0–4.Google Scholar
  34. 34.
    National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: Recognition and management. 2013. National Clinical Guideline Number 155.Google Scholar
  35. 35.
    Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RKR, Riecher-Rössler A, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3):388–404. Scholar
  36. 36.
    Pringsheim T, Addington D. Canadian schizophrenia guidelines: introduction and guideline development process. Can J Psychiatr. 2017;62(9):586–93.CrossRefGoogle Scholar
  37. 37.
    • Addington J, Addington D, Abidi S, Raedler T, Remington G. Canadian treatment guidelines for individuals at clinical high risk of psychosis. Can J Psychiatry. 2017;62(9):656–61. Most recently published clinical treatment guidelines for those at clinical high risk of psychosis.Google Scholar
  38. 38.
    Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clin Res ed). 2011;343:d5928-d. Scholar
  39. 39.
    Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–9. Scholar
  40. 40.
    Nelson B, Amminger GP, McGorry PD. Recent meta-analyses in the clinical high risk for psychosis population: clinical interpretation of findings and suggestions for future research. Front Psych. 2018;9(502).
  41. 41.
    Yung AR, Yuen HP, Berger G, Francey S, Hung TC, Nelson B, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33(3):673–81. Scholar
  42. 42.
    Addington J, Stowkowy J, Liu L, Cadenhead KS, Cannon TD, Cornblatt BA et al. Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis. Psychol Med. 2018;1–8.
  43. 43.
    Addington J, Liu L, Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, et al. North American Prodrome Longitudinal Study (NAPLS 2): the prodromal symptoms. J Nerv Ment Dis. 2015;203(5):328–35.CrossRefGoogle Scholar
  44. 44.
    Brummitt K, Author A, Kelsven S, Devoe D, Stern L, Granholm E, et al. Cognitive behavioral social skills training for youth at risk of developing psychosis. Early Interv Psychiatry. 2018;12(1):178.Google Scholar
  45. 45.
    Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A “SMART” design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012;8:21–48. Scholar
  46. 46.
    Nelson B, Amminger GP, Yuen HP, Wallis N, Kerr MJ, Dixon L, et al. Staged treatment in early psychosis: a sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Early Interv Psychiatry. 2018;12(3):292–306. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jean Addington
    • 1
    • 2
    Email author
  • Daniel J. Devoe
    • 1
    • 2
  • Olga Santesteban-Echarri
    • 1
    • 2
  1. 1.Hotchkiss Brain Institute, Department of PsychiatryUniversity of CalgaryCalgaryCanada
  2. 2.Mathison Centre for Mental Health Research & EducationUniversity of CalgaryCalgaryCanada

Personalised recommendations